Millettia

Other Names

Akar mambuAkar mumbolAwongAwoungBerrebera ferrugineaBirbiraBiribiraBokongeBori akarCaulis MillettiaeCaulis SpatholobiCha-nai-khoCytisus pinnatusDerris indicaDerris taiwanianaDianjixuetengDikelaGaledupa indicaGaledupa pinnataHongeHonge treeIndian beechIndian Beech TreeJi Xue TengJixuetengKacang kayu lautKanugaKarachKaranjKaranjaKi pahang lautMbotoMempariMibotuMillettia dielsianaMillettia ferrugineaMillettia gentlianaMillettia japonicaMillettia laurentiiMillettia nitidaMillettia pachycarpaMillettia pinnataMillettia reticulataMillettia speciosaMillettia stuhlmanniiMillettia vineMinnariMpandeNaktamalaNanhaia speciosaNatsu fujiNiudaliOtogoPalissandre du CongoPalissandro del CongoPanga pangaPhaseolodes ferrugineumPhaseoloides ferrugineaPongamPongam oiltreePongam treePongame oiltreePongamia glabraPongamia mitisPongamia pinnataPoonga-oil-treePungaiSotalloSpatholobus stemSpatholobus suberectusTshikalakalaWengéWengeXuetengYegoZaghiaZai wenge牛大力

Synopsis

Millettia: A Comprehensive Encyclopedic Reference

1. Identity and Botanical Classification

Millettia is a genus of flowering plants in the family Fabaceae. It consists of approximately 169 accepted species of shrubs, lianas, or trees, which are native to tropical and subtropical regions of sub-Saharan Africa, the Indian subcontinent, Indochina, southern China, Malesia, and New Guinea. It belongs to the subfamily Papilionoideae (Faboideae). The genus is widely distributed over the tropical regions of Africa, Australia, Asia, and America. Among all known species, 139 are reported to be endemic to Africa. Plants of this genus are either trees (49%), climbers/lianas (38%), or shrubs (13%).

Typical habitats include tropical rainforest and seasonally-dry lowland and upland forest and forest margins, woodland, thicket, wooded grassland, and secondary vegetation.

In the context of dietary supplement and natural ingredient use, the genus name "Millettia" most commonly refers to a cluster of closely related climbing vine species that produce a characteristic reddish-brown resinous stem. The primary medicinal species documented in the peer-reviewed literature include:

Millettia reticulata Benth. — one of the classical sources of the Chinese herbal drug jixueteng
Millettia dielsiana Harms — another traditional source of jixueteng
Millettia speciosa Champ. ex Benth. — widely used in southern Chinese food-medicine traditions; sometimes reclassified as Callerya speciosa
Millettia pachycarpa Benth. — extensively studied for phytochemical and pharmacological properties across Southeast Asia
Millettia pinnata (L.) Panigrahi — formerly Pongamia pinnata, an important species in South Asian traditions
Millettia ferruginea (Hochst.) Baker — an Ethiopian endemic important in African ethnomedicine
Millettia dura Dunn — a Kenyan/East African species studied for rotenoid content

"Millettia" is the common name that has been selected to refer to the stems obtained from several climbing legume shrubs containing a red resin, labeled as jixueteng in Chinese. The Chinese name describes the material as a stem (teng) with a sap having a reddish-brown color reminiscent of dried chicken's blood (ji = chicken; xue = blood).

The main species used as sources of this herb are: Spatholobus suberectus (the most common species traded today and the official species in the Pharmacopoeia of the People's Republic of China), as well as Millettia dielsiana, Millettia nitida, Millettia speciosa, Millettia gentliana, Millettia reticulata, and Millettia pachycarpa. It should be noted that in contemporary Chinese pharmaceutical practice, Spatholobus suberectus has largely replaced Millettia species as the official source of the drug, though historical and regional practice incorporated multiple Millettia species.

1.1 Nomenclature History

In the 1820s–1830s, Charles Millett, a plant collector and official with the East India Company, collected many samples of Millettia while living in Canton and Macao. He sent them to the University of Glasgow's Botanical Garden. One of the oldest references in traditional Chinese medicine is in Bencao Gangmu Shiyi ("Supplement to Compendium of Materia Medica"), where it is called jixueteng. The Chinese name literally translates to "stem of chicken's blood," which refers to the red resin present in the stems of several climbing legume shrubs.

Most of the species formerly classed in Pongamia are now included in Millettia, with the exception of Pongamia pinnata. Taxonomic revision continues to shift some well-known species: Millettia speciosa is treated by some authorities as Callerya speciosa (Champ. ex Benth.) Schot.

1.2 Common Preparations and Dosage Forms

In traditional Chinese medicine, the stems are used in herbal medicines. The branches and leaves are removed first, then the stem is sliced and allowed to dry in the sun.

Preparations documented in the literature include:

Dried stem decoction (water extract): The sliced, dried stem is decocted in water and consumed as a tea or herbal broth. In China, M. speciosa is used to treat kidney weakness, frequent cough, and bronchitis, and is also consumed as traditional food mixed with porridge and soup. Cooking in soup may help release more important nutrients for bone and tendon strengthening.
Tablet/extract preparations: A tablet made of jixueteng extract as the sole ingredient, Jixueteng Qingao Pian, is produced by the Shanghai Native Medicine Works; it is described as a treatment for bi syndrome, amenorrhea or dysmenorrhea due to deficiency of blood and/or stagnation of blood, and increasing white blood cell count in cancer patients who suffer leukopenia due to chemotherapy or radiation.
Injectable preparation: Jixueteng injection has also been prepared in China.
Root powder / concentrated decoction: A starting dosage cited in practice literature is: dried crude powder 9 to 15 grams per day; or 4:1 concentrated dried decoction, 3 to 6 grams per day.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

The use of M. speciosa as food can be traced back to the Ming (1368–1644) and Qing (1644–1912) Dynasties. According to famous Chinese traditional medicine monographs during the Qing Dynasty — Luchuan Bencao and Shengcao Yaoxing Beiyao — it was used both as food and medicine.

Millettia is considered to be bitter and sweet in flavor and warm in nature, and is associated with the Liver meridian. It treats blood deficiency and blood stasis syndromes, and helps activate the flow of qi. Millettia stem is one of the TCM "moving blood" and "supply blood" herbs used normally to treat problems such as anemia, dysmenorrhea, irregular menstruation, and amenorrhea.

Because it is a stem, TCM doctors say it is useful to treat muscle and joint pain by opening obstructions to qi flow in the meridians. Because it both nourishes and moves the blood, it is a good choice for patients with deficiency.

In Dictionary of Chinese Medicine, the simple decoction of 30 grams of Millettia given daily on a long-term basis was reported helpful for leukopenia induced by radiation therapy.

2.2 African Traditional Medicine

The genus Millettia has an important place in the pharmacopoeias of sub-Saharan Africa, with numerous therapeutic indications such as antitumoral, anti-inflammatory, antiviral, bactericidal, insecticidal, and pest-destroying.

Plants of this genus are used by some communities in Cameroon for the treatment of intestinal parasites, colic in children, and oral treatment for boils.

Millettia is a multi-purpose genus in Africa. Eight major uses have been identified, with Millettia species being mainly used for their wood and in the traditional pharmacopeias.

2.3 South and Southeast Asian Traditions

Roots or seeds of many Millettia species are traditionally employed as a fish poison throughout Southeast Asia. Roots and seeds of M. pachycarpa Benth., from India, Burma (Myanmar), Thailand, and China, are used likewise to poison fish and birds, and possess considerable insecticidal activity.

Millettia pachycarpa (Family: Fabaceae) is widely seen in India, Bangladesh, Bhutan, Myanmar, China, Taiwan, and Japan. The seeds have been used for the treatment of worm infestations, skin diseases, bruising, and as anthelmintics in the Southeast Asia region, whereas the root barks have been used to treat intestinal infections by direct consumption. Root peels have been used as insecticides and fish poison.

In Peninsular Malaysia, pounded leaves of M. xylocarpa Miq. (syn. M. hemsleyana Prain) are placed in a hollow tooth to relieve toothache.

2.4 Ayurvedic and Unani Use

Plants belonging to this genus are used in Ayurveda, Unani, and Chinese medicine as ethnomedicine. Plants in this genus are used as folkloric medicine for the treatment of different ailments like wound healing, boil, sores, skin diseases, snake bite, muscle aches, pains, rheumatic arthritis, and gynaecological diseases.

2.5 General Ethnobotanical Uses

Species are used locally as fuelwood, fish poisons, insecticides, medicine, ornamentals, and nitrogen fixers for soil rehabilitation in agroforestry.

3. Key Constituents and Active Compounds

Isolated compounds from the genus include flavonoids, phenolic compounds, phytosterols, saponins, alkaloids, polysaccharides, terpenoids, and resins.

The major chemical classes and their representative compounds are detailed below:

3.1 Isoflavonoids and Rotenoids

There are approximately 260 known species in the genus Millettia, many of which are used in traditional medicine to treat human and other animal ailments in various parts of the world. Being in the Leguminosae (Fabaceae) family, Millettia species are rich sources of isoflavonoids. In the past three decades alone, several isoflavonoids originating from Millettia have been isolated, and their pharmacological activities have been evaluated against major diseases such as cancer, inflammation, and diabetes.

According to the literature, 154 structurally diverse isoflavonoids were isolated and reported from the various tissues of nine well-known Millettia species. Prenylated isoflavonoids and rotenoids were the most dominant subclasses. Other subclasses include isoflavans, aglycone isoflavones, glycosylated isoflavones, geranylated isoflavonoids, phenylcoumarins, pterocarpans, and coumaronochromenes.

Key identified rotenoids from Millettia species include deguelin, tephrosin, rotenone, sumatrol, elliptol, and newly characterized species-specific compounds such as millettiapachycarpin from M. pachycarpa. A phytochemical investigation of the root and leaf extracts of Millettia pachycarpa Benth resulted in the isolation and identification of 16 compounds, including six rotenoids and 10 prenylated isoflavonoids.

3.2 Flavonoids

Flavonoids are among the most abundant and pharmacologically active secondary metabolites in M. speciosa. Targeted phytochemical analyses have identified 35 distinct flavonoids in M. speciosa Champ., with maackiain and formononetin as the major bioactive constituents.

The literature reports the occurrence of various types of active constituents from M. speciosa, which include saponins, phenolic glycosides, pterocarpans, flavonoids, isoflavonoids, and sterols.

The genus Millettia contains flavonoids, phenolic compounds, alkaloids, and terpenoids. Approximately 148 phytoconstituents have been isolated, with 73 being classified as flavonoids.

3.3 Phenolic Acids and Phytosterols

Bioactive components of M. speciosa include flavonoids, phenolic acids, alkaloids, saponins, and polysaccharides.

Various important phytocomponents have been revealed by gas chromatography-mass spectroscopy (GC-MS) analysis. Based on abundance, the major compounds identified in M. speciosa stem extracts were n-hexadecanoic acid (16.654%), n-hexadecanoic acid (14.808%), and beta-sitosterol (6.298%) for petroleum ether, ethyl acetate, and methanol extract fractions, respectively.

Gamma-sitosterol has demonstrated immune-regulatory properties, enhancing immune responses and strengthening pathogen defense.

3.4 Saponins and Polysaccharides

Saponins are reported from multiple Millettia species. A saponin has been reported from the roots of M. duchesnei. Polysaccharides isolated from Millettia are associated with immune-modulatory properties in preclinical studies, though the specific molecular characterization varies across species.

3.5 Mechanisms of Action — Established in Preclinical Research

Targeted phytochemical analyses have identified maackiain and formononetin as the major bioactive constituents of M. speciosa. Maackiain has demonstrated strong antioxidant and anti-inflammatory properties, primarily through the inhibition of reactive oxygen species (ROS) generation and downregulation of pro-inflammatory cytokines, offering protective effects against cardiovascular and metabolic disorders.

Formononetin exhibits notable anticancer potential by promoting apoptosis and suppressing proliferation in breast and lung cancer models.

Rotenone is widely regarded as the main culprit of the toxic symptoms attributed to some Millettia species; as a lipophilic compound, it traverses biological membranes, including the blood–brain barrier, and directly affects cells by inhibiting mitochondrial complex I of the electron transport chain. This action decreases adenosine triphosphate (ATP) formation, leading to cell death.

Several in vitro and in vivo studies have shown that various classes of Millettia isoflavonoids have anti-inflammatory properties. In vitro studies with macrophage cells (RAW264.7) showed that multiple isoflavonoid compounds — including (3S)-vestitol, Brandisianin A, scandenone, diprenyorobol, and 6,8-milletenol A — inhibit the production of nitric oxide (NO), one of the known inflammatory mediators. The IC50 values of these molecules ranged from 8.5 to 35.7 µM, with scandenone being the most potent molecule.

4. Scientific Evidence by Area of Use

4.1 Hematopoietic Support and Leukopenia

Evidence level: Preliminary; limited to historically reported Chinese clinical series and animal studies. No modern randomized controlled trials (RCTs) identified.

During the 1980s and up to more recently, several clinical trials were conducted involving treatment of leukopenia and thrombocytopenia in which Millettia was included in herbal formulas, and results of the therapy were reported in Chinese medical journals. These trials, however, involved compound multi-herb formulas rather than Millettia as an isolated intervention, limiting attributability.

Clinical studies in China on cancer patients with impaired immune function using various compound formulas containing Millettia stem have shown increases in white blood cell function, hemoglobin, and platelets. These reports are historical and largely confined to Chinese-language publications; they do not meet current standards for clinical evidence.

In Dictionary of Chinese Medicine, the simple decoction of 30 grams of Millettia given daily on a long-term basis was reported helpful for leukopenia induced by radiation therapy. This is a documented traditional clinical report rather than a controlled study.

4.2 Anti-Inflammatory Activity

Evidence level: Preclinical (in vitro and limited in vivo animal studies). No human clinical trials identified.

Several in vitro and in vivo studies have shown that various classes of Millettia isoflavonoids have anti-inflammatory properties. In vitro studies with macrophage cells (RAW264.7) showed that multiple isolated isoflavonoid compounds inhibit the production of NO, one of the known inflammatory mediators.

Other in vivo studies have shown that griffonianone D inhibits swelling in ATP- and PLA2-induced edema assays. Millettia pachycarpa exhibits anti-inflammatory activity through the suppression of LPS-induced NO/iNOS expression.

Other pharmacological effects of compounds and extracts of Millettia include inhibition of interleukin-1 production by pongapinone A, a phenylpropanoid isolated from the bark of M. pinnata.

4.3 Anticancer / Cytotoxic Activity

Evidence level: Preclinical only (in vitro cell-line studies). No human clinical trials identified.

Hydroxyrotenone and rotenone showed significant cytotoxicity against HT-29 (colorectal cancer) cells with IC50 values of 0.1 and 0.3 µM, respectively, whereas barbigerone showed significant cytotoxicity against HepG2 (hepatocellular carcinoma) cell lines with an IC50 value of 0.61 µM.

Compounds 3, 9, 11, 12, 15, and 16 from M. pachycarpa were cytotoxic against all cell lines tested, with cell viability in the range of 4.53–48.19%.

Anticancer effects of flavonoid derivatives isolated from Millettia reticulata Benth have been investigated in SK-Hep-1 human hepatocellular carcinoma cells. These are in vitro findings and cannot be extrapolated to clinical efficacy without human trial data.

Although some isolated molecules showed promising pharmacological properties, such as anticancer, anti-inflammatory, estrogenic, and antibacterial activities, others remained untested.

4.4 Antidiabetic Activity

Evidence level: Preclinical only (enzyme inhibition assays and in vitro studies). No human clinical trials identified.

Antidiabetic activities, including α-glucosidase and α-amylase inhibitory activities, and cytotoxicities against human cancer cell lines (lung cancer A549, colorectal cancer SW480, and leukemic K562 cells) were assessed for compounds isolated from M. pachycarpa.

4′,5′-Dimethoxy-6,6-dimethylpyranoisoflavone and deguelin showed butyrylcholinesterase inhibitory activity with IC50 values of 2.34 and 14.25 µM, respectively, whereas tephrosin had anti-inflammatory activity with an IC50 value of <10 µM.

Dandelion sterol (from M. speciosa) exhibits notable antidiabetic potential in preclinical assessment, though human data are absent.

4.5 Antimicrobial Activity

Evidence level: Preclinical only (in vitro assays). No human clinical trials identified.

Millettia extensa and M. pinnata extracts exhibit significant antimicrobial activity in in vitro screening studies. The genus has been noted for antibacterial properties across multiple species and extract types, but these findings remain confined to laboratory settings.

4.6 Antioxidant Activity

Evidence level: Preclinical (in vitro assays). No human clinical trials identified.

A study to determine the total flavonoid content (TFC) and pharmacological activities of different fractions of M. speciosa stem showed that different organic solvents of increasing polarity were used for extraction. The highest total flavonoid content — 48.30 ± 0.90% — was reported for the petroleum ether extract.

M. speciosa and its by-products have shown notable biological activities including antioxidant, antimicrobial, anti-inflammatory, and anticancer effects.

4.7 Neuroprotective / Cholinesterase Inhibitory Activity

Evidence level: Preclinical only (in vitro enzyme inhibition). No human clinical trials identified.

Millettia pachycarpa Benth, a widely used anthelmintic drug in folk medicine, is rich in flavonoids with various bioactivities. A study aimed to identify active flavonoids with anti-Alzheimer's disease effect from its seeds by bioassay-guided isolation. A novel rotenoid with an unusual oxidative ring-opening skeleton and nine known flavonoids were obtained. Among all isolates, two compounds showed selective butyrylcholinesterase (BChE) inhibitory activities (IC50 = 2.34 and 11.49 µM, respectively), while a third was classified as a dual-action inhibitor against acetylcholinesterase (AChE) and BChE. Further kinetic study revealed mixed-type BChE inhibition, and their binding affinities to BChE were confirmed by fluorescence quenching analysis.

4.8 Insecticidal and Larvicidal Activity

Evidence level: Preclinical (laboratory bioassays). Relevant primarily as a toxicological concern rather than a therapeutic application.

The crude extract of seeds of Millettia dura in chloroform was highly toxic (24-hour LC50: 3.5 ppm) to second-instar Aedes aegypti larvae. The rotenoids deguelin and tephrosin, isolated from the seeds of this plant, also showed potent mosquitocidal activities (24-hour LC50 ranging from 1.6 to 1.4 ppm).

Many plants of the Leguminosae family, especially in the genera Derris, Lonchocarpus, Millettia, Mundulea, and Tephrosia, are used as fish poison and insecticides.

4.9 Antiprotozoal Activity

Evidence level: Preclinical only (in vitro). No human clinical trials identified.

At least 60% of Millettia species are known for their medicinal properties, and researchers have assessed the potential antiprotozoal and antifungal activities of some species. In vitro screening studies have examined extracts of species such as M. richardiana from Madagascar for antiprotozoal and antifungal properties, with aqueous and methanolic extracts both evaluated.

5. Body Systems and Health Areas

Based on the documented traditional uses and preclinical scientific literature, the genus Millettia is associated with effects on the following body systems and health areas:

Hematopoietic and circulatory system: Traditional use for anemia, blood deficiency, leukopenia, thrombocytopenia, and blood-nourishing functions in TCM. Millettia stem is used to treat problems such as anemia, dysmenorrhea, irregular menstruation, and amenorrhea.
Musculoskeletal system: Used as folkloric medicine for muscle aches, pains, and rheumatic arthritis.
Reproductive system: In modern times, Millettia has been used to regulate menstruation, and treat related conditions such as menstrual bleeding, dysmenorrhea, and anemia.
Immune system: Preclinical evidence for immune-regulatory properties via polysaccharides and phytosterols; historically reported use in formulas for chemotherapy-related immune suppression.
Integumentary system (skin): Several Millettia species have emerged as high-quality medicine in a traditional system for wound healing and skin diseases.
Oncology / cancer-related supportive care: Historical reports of use in formulas addressing chemotherapy and radiation side effects; in vitro cytotoxicity of isolated compounds against multiple cancer cell lines.
Metabolic / endocrine system: Preclinical antidiabetic properties (alpha-glucosidase and alpha-amylase inhibition) from isolated rotenoids and isoflavonoids.
Nervous system: In vitro cholinesterase inhibitory activity suggesting potential relevance to neurodegenerative conditions; no clinical data available.
Respiratory system: In China, M. speciosa is used to treat kidney weakness, frequent cough, and bronchitis.
Infectious diseases: Traditional uses for intestinal parasites, snakebite, and skin infections; in vitro evidence for antimicrobial and antiprotozoal activity.

6. Dosage Forms Reported in the Literature

All dosages below are drawn from source documents and represent reported practice or study parameters, not recommendations:

Simple decoction (dried stem, jixueteng): 30 grams per day, given on a long-term basis, reported for leukopenia induced by radiation therapy.
Dried crude powder: 9 to 15 grams per day. 4:1 concentrated dried decoction: 3 to 6 grams per day.
Pharmaceutical tablet (Jixueteng Qingao Pian): Standardized jixueteng extract tablet; the specific per-tablet dosage is determined by the manufacturer (Shanghai Native Medicine Works) and referenced in Chinese pharmaceutical texts, but exact per-dose quantity is not independently verifiable in the peer-reviewed sources retrieved.
Food preparation (M. speciosa): Mixed with porridge and soup as traditional food. Cooking in soup may help release important nutrients for bone and tendon strengthening.

No standardized dosage for any Millettia species has been established through clinical pharmacokinetic or dose-finding trials in humans. All dosage information is derived from traditional practice documentation or non-clinical sources.

7. Safety Considerations

7.1 Rotenoid Toxicity

Rotenone is widely regarded as the main culprit of toxic symptoms arising from Millettia species. As a lipophilic compound, it traverses biological membranes including the blood–brain barrier, and directly affects cells by inhibiting mitochondrial complex I of the electron transport chain, decreasing ATP formation and leading to cell death. This toxicity is nonselective, affecting all cells in an organism, with clinical features predominantly neurological due to the greater vulnerability of the central nervous system. A case has been reported of an elderly male who accidentally ingested the fruit of M. pachycarpa Benth.

Rotenone has high acute toxicity to mammals, and all insecticidal uses were banned in the United States and Canada, the EU, the UK, and Switzerland. This toxicological profile of rotenone is relevant because it is a significant constituent of certain Millettia species, particularly M. pachycarpa and M. dura, and its presence in raw plant material constitutes a material safety concern with any ingestion of concentrated extracts.

7.2 Fish Poison and Ichthyotoxic Properties

Roots or seeds of many Millettia species are traditionally employed as a fish poison throughout Southeast Asia. Roots and seeds of M. pachycarpa are used to poison fish and birds, and possess considerable insecticidal activity. The same compounds responsible for fish toxicity (principally rotenoids) are present in material marketed for medicinal use, and this dual nature represents an inherent safety concern.

7.3 Cardiovascular Effects

Hsu has noted hypotensive effects for some Millettia preparations, which could interact with antihypertensive medications, though this is based on traditional pharmacological observation rather than clinical pharmacological study.

7.4 Potential Drug Interactions

Millettia stem should be used cautiously if taking blood-thinning medication, based on its TCM classification as a blood-moving herb.

7.5 Species Authentication and Adulteration

Spatholobus suberectus is the most common species traded today and the official species in the Pharmacopoeia of the People's Republic of China. Multiple Millettia species may be sold under the same jixueteng label, and the toxicological profiles differ substantially between species, particularly regarding rotenoid content. Species with high rotenoid loads (notably M. pachycarpa) carry significantly more acute toxicity risk than stem-derived preparations from M. reticulata or M. dielsiana.

7.6 Pregnancy and Special Populations

No formal teratogenicity or reproductive toxicology studies in humans have been retrieved. Given that some Millettia preparations are used specifically in gynaecological conditions (amenorrhea, dysmenorrhea), and given the blood-moving pharmacology described in TCM, caution is historically advised in pregnancy — but this is a traditional clinical judgment, not an evidence-based pharmacological finding from clinical studies.

7.7 Evidence Gaps in Safety

Traditional uses are validated by performing different animal studies; clinical trials are required to measure safety and efficacy in human beings as part of the drug development process. Safety evaluations based on existing toxicological and pharmacokinetic studies of M. speciosa have been summarized in recent literature, but comprehensive human safety data remain lacking across the genus.

8. Current State of Research and Evidence Summary

Several Millettia species have emerged as high-quality medicine in a traditional system for arthritis, wound healing, inflammation, and skin diseases. Numerous conventional uses of Millettia species have been validated by modern pharmacology research. Intensive investigations of the genus Millettia relating to phytochemistry and pharmacology, especially their mechanism of action, safety, and efficacy, are identified as future research priorities in the area of phytomedicine.

Despite promising results in preclinical studies, many of the isolated Millettia isoflavonoids remain untested in rigorous human studies. The current body of evidence is predominantly composed of: (1) documented traditional use across multiple ethnomedical systems; (2) phytochemical characterization of isolated compounds; (3) in vitro cell-line and enzyme-inhibition studies; and (4) a small number of in vivo animal model experiments. Robust randomized controlled trials in human subjects are absent from the published record for any therapeutic claim associated with the genus Millettia.

Despite the extensive body of research, several key issues remain. First, the bioactive components present in various parts of Millettia species (such as leaves, flowers, seeds, and stems) have not been fully identified.

References

Health Conditions

Health conditions that Millettia may help support.

No conditions available.

Body Systems

Body systems that Millettia may help support.

No body systems available.